跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
XARELTO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
XARELTO
Authorized
STANDARD
XARELTO
Bayer Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
c28374112fb94084
Company
Bayer Inc
Type
Standard
Approval Details
Approval Id
c28374112fb94084
Drug Approval Canada Name
XARELTO
Product Name
XARELTO
Status
Marketed
Status Date
2021-06-11
Original Market Date
2021-06-11
Din
02510170
Drug Class
Human
Dosage Form
Granules For Suspension
Route Of Administration
Oral
Schedule
Prescription
Ahfs
20:12.04.14
Atc Original
B01AF01 RIVAROXABAN
Atc Name
b 01 af 01
Aig Number
0152487008
Company Name
Bayer Inc
Company Address
2920 Matheson Blvd East, Mississauga, Ontario, Canada, L4W 5R6
Active Ingredients
RIVAROXABAN
103.4 MG / BOTTLE
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
c28374112fb94084
Type
Standard
Back to Health Canada Approvals